Bitcoin price today: nosedives to 6-mth low below $96k as Dec rate cut bets wane
Investing.com -- Caribou Biosciences Inc. (NASDAQ:CRBU) stock soared 100% following the announcement of positive Phase 1 data for its CB-011 therapy in relapsed or refractory multiple myeloma patients.
The clinical-stage CRISPR genome-editing company reported a 92% overall response rate and 75% complete response rate or better in a 12-patient cohort treated with the recommended dose for expansion. The data came from the company’s ongoing CaMMouflage Phase 1 trial evaluating CB-011, an off-the-shelf anti-BCMA CAR-T cell therapy.
Among the highlights, 91% of evaluable patients achieved minimal residual disease negativity, and seven of the 12 patients remained in very good partial response or better six months after receiving a single dose of CB-011. The longest responding patient has maintained a stringent complete response at 15 months post-infusion.
"We are very encouraged by the compelling results from the CaMMouflage phase 1 trial, which demonstrate that CB-011 is delivering deep, durable responses in high-risk, heavily pretreated multiple myeloma patients with a manageable safety profile," said Rachel Haurwitz, PhD, Caribou’s president and chief executive officer.
The company reported that CB-011 demonstrated a manageable safety profile across all dose levels, with no cases of graft-versus-host disease. However, there were some notable adverse events, including one treatment-related grade 5 immune effector cell-associated hematotoxicity.
Caribou plans to advance the program into dose expansion by the end of this year, with expansion data expected in 2026.
The therapy could potentially address significant treatment gaps, as currently only 10% of eligible multiple myeloma patients receive autologous CAR-T therapy, according to Dr. Adriana Rossi, an investigator on the trial.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.